Multicentre Phase II Trial Evaluating Stereotactic Body Radiotherapy on Ultra-central Lung Tumors on MR-Linac

Phase II multicenter trial evaluating the safety, tolerability, and feasibility of MRI-guided stereotactic radiotherapy using MRI-LINAC in patients with ultracentral lung tumors or lymphadenopathy in the context of controlled oligometastatic disease. The study investigates the potential of this innovative technology, which enables real-time treatment adaptation, with the goal of optimizing the benefit-risk ratio in a population at high risk of radiotherapy-related toxicity

NCT Number	NCT07733219
Lead Sponsor	Centre Oscar Lambret Collaborators: Aquilab SAS, Centre François Baclesse (CTD-CNO)
Conditions	Ultracentral Pulmonary Tumors, Lung Cancer (T1 N0 M0 and T2 N0 M0), Mediastinal Lymph Node Recurrence From All Types of Primary Cancer, Pulmonary Node Recurrence From All Types of Primary Cancer
Enrollment	59 participants
Start Date	2026-09-01
Primary Completion	2031-11-01 (estimated)
Study Completion	2031-11-01 (estimated)
Updated on ClinicalTrials.gov	2026-07-29